Guidelines

P18 Ibrutinib, the first available BTK inhibitor: single centre experience

February 2019
P19 Receptor tyrosine kinase AXL: a potential new target in multiple myeloma

February 2019
P20 Contribution of next-generation sequencing analysis to the differential diagnosis of cutaneous lesions suspected of lymphoma

February 2019
P21 Acute hepatitis after chlorambucil alone for chronic lymphocytic leukaemia (CLL)

February 2019
P22 Validation of a single 10-colours tube facilitating discrimination of monoclonal from polyclonal plasma cells in indolent myeloma

February 2019
P23 Amitryptilin strengthens effects of bortezomib and melphalan treatment in multiple myeloma by inhibiting acid sphingomyelinase

February 2019
P24 MRD discrepancy during follow-up of p190 BCR-ABL1+ childhood B-ALL: diagnosis of a ‘CML-like’ all subgroup

February 2019
P25 Comparison of Multigam® IV (5% 10%) in haematological patients with a secondary immunodeficiency to evaluate infusion time, tolerability and satisfaction. A monocentric observational Belgian study

February 2019
P26 Long-term follow-up of 2 patients treated with Y-rituximab radioimmunotherapy for relapse of predominantly lymphocytic nodular hodgkin’s lymphoma

February 2019
P27 PCLO is overexpressed in ETV6-RUNX1-positive B-cell precursor acute lymphoblastic leukaemia

February 2019

Top